Results

Transgene SA

05/27/2019 | Press release | Distributed by Public on 05/27/2019 09:54

May 27, 2019 - Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)